Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.

In this study of 454 ICU survivors of severe COVID-19 one year after discharge, 10.2% mortality was observed, and substantial declines in health-related quality of life and increased frailty were reported, implying a need for comprehensive post-ICU care.

This study found that P144 (Disitertide) significantly reduced collagen deposition and improved muscle organization in a rabbit model of post-radiotherapy fibrosis, suggesting potential antifibrotic effects.

This study investigated the identity of Victor Vinnetou as Mbuyisa Makhubu using forensic facial comparison and DNA testing, but the findings were inconclusive, requiring further investigation.

The authors concluded that VSCAPSI, a videodermoscopy-based assessment tool, provides evidence for early diagnosis, differential diagnosis, follow-up, and screening of scalp psoriasis.

This study found that the SAAD-41 is a validated tool for assessing psychosocial outcomes in individuals with alopecia areata, showing strong correlations with established measures of quality of life and coping.

This study developed two comprehensive patient-reported outcome measures for systemic lupus erythematosus to assess symptom fluctuations and impacts, following FDA guidelines, which may aid in clinical studies and practice.

This study found that the Alopecia Areata Patient Priority Outcomes questionnaire is a reliable and valid tool for measuring the severity and impact of hair loss in individuals with alopecia areata.

This study developed a standardized questionnaire to measure patient-perceived changes in hair growth and appearance, which showed significant favoring of active treatment over placebo in a clinical trial for male androgenetic alopecia.

This survey found support among BAAPS members for using procedure-specific consent forms to improve clarity and consistency in patient information for aesthetic procedures.

This study evaluated an online survey tool designed to identify polycystic ovary syndrome, identifying areas for improvement that can aid in accurately assessing PCOS prevalence in general populations.

This research found that the Hair & Scalp CARE questionnaire is an effective tool for assessing the impact of scalp and hair condition on psychological wellbeing, and suggests healthier hair and scalp are linked to lower stress and better sleep.

This study presents a new survey instrument that was cognitively tested for understanding menstrual cycle characteristics and androgen excess, including hirsutism, alopecia, and acne.

This study developed and initially validated the Scale of Alopecia Areata Distress (SAAD), a 41-item tool designed to measure psychosocial distress among US adults with alopecia areata.

This study developed a handheld card to simplify the calculation of the SALT score for assessing alopecia areata severity, noting that while it accelerates the process, formal validation against existing methods is still needed.

This review assessed patient-reported outcome measures for alopecia treatments but found that none met current FDA guidelines; however, some could potentially be adapted for more comprehensive use.

This study concluded that the Scalp Photographic Index is a reliable and validated tool for objectively classifying and scoring various scalp conditions.

This study developed the SAALIQ, a culturally adapted tool specifically for measuring quality of life in Spanish-speaking patients with alopecia areata, highlighting its strong psychometric performance and the benefit of capturing overlooked domains compared to generic measures.

This study describes the development of the EUSCLE Core Set Questionnaire for cutaneous lupus erythematosus, designed to standardize data collection, facilitate epidemiological analysis, and guide diagnostic and therapeutic strategies across European centers.

This study developed and validated the Hair-Shedding Visual Scale for Asian Women, finding it to be an effective tool for identifying FPHL and TE.

This review found that the only PCOS-specific quality of life measure, the PolyCystic Ovary Syndrome Questionnaire, has an incomplete development history and lacks some essential measurement properties for clinical trial use.

This study found that the Alopecia Areata Symptom Impact Scale (AASIS) is a better tool than the Alopecia Areata Quality of Life Index (AA-QLI) for assessing patient-reported outcomes in alopecia areata.

This study reports that even minimal improvements in SLE-related fatigue and skin symptoms are meaningful to patients, supporting the content validity of the FACIT-Fatigue scale for measuring these effects.

This study found that the revised 43-item PCOSQ had better validity and reliability than the original version, although further studies are needed to assess its predictive efficacy.

This Delphi survey study identified six key domains that should be measured in all future psoriasis clinical trials to ensure comprehensive assessment, including skin manifestations and treatment satisfaction.

This study found that alopecia areata significantly impacts patients' quality of life irrespective of hair loss severity, and concluded that the newer assessment tools AAPPO and AASIS better capture this impact compared to the traditional SALT measure.

This study found that the scalp coverage scoring (SCS) method is a non-invasive and reproducible technique that effectively measures hair growth and loss dynamics in male subjects with androgenetic alopecia.

This study highlights ongoing limitations in the administration and reporting of FACE-Q Aesthetic scale data, recommending that future research follow the User's Guide for proper administration and scoring, justify the study's time frame, and provide sample size calculations for key outcomes.

This study found that the Spanish version of the hair-specific Skindex-29 questionnaire effectively detected changes in health-related quality of life among women with female-pattern hair loss, and the scores were significantly correlated with the SF-12 survey results after treatment with a 5 alpha-reductase inhibitor.